These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11642523)

  • 21. Iloprost treatment of finger gangrene in a patient with Raynaud's syndrome.
    Levy Y; Sherer Y; Shoenfeld Y
    Isr Med Assoc J; 2000 Dec; 2(12):960-1. PubMed ID: 11344792
    [No Abstract]   [Full Text] [Related]  

  • 22. Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome).
    Clark DW; Correa-Nunes AM; Edwards IR
    Eur J Clin Pharmacol; 2003 Jul; 59(3):261-2. PubMed ID: 12756515
    [No Abstract]   [Full Text] [Related]  

  • 23. Possibilities for clinical use of prostacyclin in vascular disease.
    Poredos P
    Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases].
    García Hernández FJ; Ocaña Medina C; Mateos Romero L; Molinillo López J; Arias Zambrano A; González León R; Sánchez Román J
    Med Clin (Barc); 2004 Apr; 122(13):501-4. PubMed ID: 15104947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
    McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ
    Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iloprost infusion through elastomeric pump for the outpatient treatment of severe Raynaud's phenomenon and digital ulcers - a single centre experience.
    Duarte AC; Barbosa L; Santos MJ; Cordeiro A
    Acta Reumatol Port; 2018; 43(3):237-238. PubMed ID: 30414374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe digital necrosis in a 4-year-old boy: primary Raynaud's or jellyfish sting.
    Binnetoglu FK; Kizildag B; Topaloglu N; Kasapcopur O
    BMJ Case Rep; 2013 Nov; 2013():. PubMed ID: 24248320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
    Lamprecht P; Schnabel A; Gross WL
    Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
    Rembold CM; Ayers CR
    Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.
    Rademaker M; Thomas RH; Provost G; Beacham JA; Cooke ED; Kirby JD
    Postgrad Med J; 1987 Aug; 63(742):617-20. PubMed ID: 2447572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of digital artery adrenoceptors in Raynaud's disease.
    Cooke JP; Creager SJ; Scales KM; Ren C; Tsapatsaris NP; Beetham WP; Creager MA
    Vasc Med; 1997; 2(1):1-7. PubMed ID: 9546943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of digital ischaemia associated with chemotherapy using the prostacyclin analogue iloprost.
    Vowden P; Wilkinson D; Kester RC
    Eur J Vasc Surg; 1991 Oct; 5(5):593-5. PubMed ID: 1720404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactive hyperemia in Raynaud's disease.
    Pratesi F; Corsi C; Deidda C; Nuti A
    Biochem Exp Biol; 1977; 13(3):337-9. PubMed ID: 16296018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases.
    Zulian F; Corona F; Gerloni V; Falcini F; Buoncompagni A; Scarazatti M; Martini G; Zacchello F
    Rheumatology (Oxford); 2004 Feb; 43(2):229-33. PubMed ID: 12923288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon.
    Cekic S; Kilic SS
    Lupus; 2016 Apr; 25(5):558-60. PubMed ID: 26692039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.